Molecular Cancer Therapeutics

Table of Contents

AACR American Association for Cancer Research

October 2017 • Volume 16 • Number 10

Highlights of This Issue 2045

SMALL MOLECULE THERAPEUTICS

Table of Contents

LARGE MOLECULE THERAPEUTICS

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

Table of Contents

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

LETTER TO THE EDITOR

RETRACTION

AC icon indicates AuthorChoice
For more information please visit www.aacrjournals.org

ABOUT THE COVER

Quantitative liquid chromatography/mass spectrometry (LC/MS) metabolomics in two BRAF mutant human melanoma xenograft models (WM266.4 and A375), were used to select the metabolites increased or decreased in tumor versus non-tumor bearing animals, whose changes were reversed by the MEK inhibitor RO4987655. Of these 21 metabolites identified preclinically in these models that were sensitive to MEK inhibition, 15 on-treatment changes were significantly correlated with objective responses in patients with advanced melanoma treated with RO4987655 and seven metabolite levels had pre-treatment predictive value. For more details see the article by Ang and colleagues (beginning on page 2315).



Molecular Cancer Therapeutics

16 (10)

Mol Cancer Ther 2017;16:2045-2326.